{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=50",
    "query": {
      "condition": "Ovary Disease",
      "page": 50
    },
    "page_size": 10
  },
  "pagination": {
    "page": 50,
    "page_size": 10,
    "total_count": 2269,
    "total_pages": 227,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=51&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=49&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T04:51:10.850Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03944902",
      "title": "CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Resistant BRCA Wild-Type Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Cohort 1: Dose Escalation",
          "type": "DRUG"
        },
        {
          "name": "Cohort 2: Dose Escalation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1,
      "start_date": "2021-09-01",
      "completion_date": "2022-01-05",
      "has_results": false,
      "last_update_posted_date": "2023-11-21",
      "last_synced_at": "2026-11-02T04:51:10.850Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03944902"
    },
    {
      "nct_id": "NCT04257045",
      "title": "Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Carcinoma",
        "Deleterious CDH1 Gene Mutation",
        "Deleterious DICER1 Gene Mutation",
        "Deleterious SMARCA4 Gene Mutation",
        "Deleterious STK11 Gene Mutation",
        "Endometrial Carcinoma",
        "Fallopian Tube Carcinoma",
        "Ovarian Carcinoma",
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Interview",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2019-08-21",
      "completion_date": "2024-07-09",
      "has_results": false,
      "last_update_posted_date": "2024-07-12",
      "last_synced_at": "2026-11-02T04:51:10.850Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Houston, Texas",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04257045"
    },
    {
      "nct_id": "NCT04503265",
      "title": "A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Neoplasm",
        "Breast Cancer",
        "Ovarian Cancer",
        "Homologous Recombination Deficiency",
        "Prostate Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "AMXI-5001:Dose Escalation Phase I",
          "type": "DRUG"
        },
        {
          "name": "AMXI-5001:Dose Expansion Phase II",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AtlasMedx, Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2020-08-12",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2025-05-01",
      "last_synced_at": "2026-11-02T04:51:10.850Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04503265"
    },
    {
      "nct_id": "NCT01931644",
      "title": "At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "All Diagnosed Health Conditions",
        "ADD/ADHD",
        "Alopecia Areata",
        "Ankylosing Spondylitis",
        "Asthma",
        "Atopic Dermatitis Eczema",
        "Beta Thalassemia",
        "Bipolar Disorder",
        "Breast Cancer",
        "Celiac Disease",
        "Cervical Cancer",
        "Chronic Inflammatory Demyelinating Polyneuropathy",
        "Chronic Kidney Diseases",
        "Chronic Obstructive Pulmonary Disease",
        "Colon Cancer",
        "Colorectal Cancer",
        "Crohn's Disease",
        "Cystic Fibrosis",
        "Depression",
        "Diabetes Mellitus",
        "Duchenne Muscular Dystrophy",
        "Endometriosis",
        "Epilepsy",
        "Facioscapulohumeral Muscular Dystrophy",
        "G6PD Deficiency",
        "General Anxiety Disorder",
        "Hepatitis B",
        "Hereditary Hemorrhagic Telangiectasia",
        "HIV/AIDS",
        "Human Papilloma Virus",
        "Huntington's Disease",
        "Idiopathic Thrombocytopenic Purpura",
        "Insomnia",
        "Kidney Cancer",
        "Leukemia",
        "Lung Cancer",
        "Lupus Nephritis",
        "Lymphoma",
        "Melanoma",
        "Multiple Myeloma",
        "Multiple Sclerosis",
        "Myositis",
        "Myotonic Dystrophy",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Parkinson's Disease",
        "Polycystic Kidney Diseases",
        "Prostate Cancer",
        "Psoriasis",
        "Psoriatic Arthritis",
        "Rosacea",
        "Scleroderma",
        "Sickle Cell Anemia",
        "Sickle Cell Trait",
        "Sjogren's Syndrome",
        "Skin Cancer",
        "Spinal Muscular Atrophy",
        "Systemic Lupus Erythematosus",
        "Thrombotic Thrombocytopenic Purpura",
        "Trisomy 21",
        "Ulcerative Colitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Sanguine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 17667,
      "start_date": "2013-07",
      "completion_date": "2024-04",
      "has_results": false,
      "last_update_posted_date": "2024-04-18",
      "last_synced_at": "2026-11-02T04:51:10.850Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01931644"
    },
    {
      "nct_id": "NCT03349463",
      "title": "Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cervical Cancer",
        "Endometrial Cancer",
        "Ovarian Epithelial Cancer"
      ],
      "interventions": [
        {
          "name": "Fluciclovine F18",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bital Savir-Baruch",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2018-11-14",
      "completion_date": "2020-12",
      "has_results": false,
      "last_update_posted_date": "2020-02-28",
      "last_synced_at": "2026-11-02T04:51:10.850Z",
      "location_count": 1,
      "location_summary": "Maywood, Illinois",
      "locations": [
        {
          "city": "Maywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03349463"
    },
    {
      "nct_id": "NCT00083122",
      "title": "Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Primary Peritoneal Cavity Cancer",
        "Stage IIIA Ovarian Epithelial Cancer",
        "Stage IIIA Primary Peritoneal Cavity Cancer",
        "Stage IIIB Ovarian Epithelial Cancer",
        "Stage IIIB Primary Peritoneal Cavity Cancer",
        "Stage IIIC Ovarian Epithelial Cancer",
        "Stage IIIC Primary Peritoneal Cavity Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "alvocidib",
          "type": "DRUG"
        },
        {
          "name": "cisplatin/flavopiridol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 45,
      "start_date": "2004-04",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2014-05-21",
      "last_synced_at": "2026-11-02T04:51:10.850Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00083122"
    },
    {
      "nct_id": "NCT00040911",
      "title": "Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Brain Tumors",
        "Central Nervous System Tumors",
        "Childhood Germ Cell Tumor",
        "Extragonadal Germ Cell Tumor",
        "Head and Neck Cancer",
        "Lymphoma",
        "Nausea",
        "Vomiting",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "electroacupuncture therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "sham intervention",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "5 Years to 35 Years"
      },
      "enrollment_count": 17,
      "start_date": "2005-04",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2013-05-31",
      "last_synced_at": "2026-11-02T04:51:10.850Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00040911"
    },
    {
      "nct_id": "NCT02831556",
      "title": "Point of Care 3D Ultrasound for Various Applications: A Pilot Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Appendicitis",
        "Evidence of Cholecystectomy",
        "Gallstones",
        "Pregnancy, Ectopic",
        "Aortic Aneurysm",
        "Kidney Stones",
        "Intrauterine Pregnancy",
        "Diverticulitis",
        "Abdominal Injuries",
        "Tumors",
        "Pancreatitis",
        "Digestive System Diseases",
        "Gastrointestinal Diseases",
        "Intraabdominal Infections",
        "Intestinal Diseases",
        "Pregnancy",
        "Vascular Disease",
        "Uterine Fibroids",
        "Ovarian Cysts",
        "Uterine Abnominalies",
        "Bladder Abnominalies",
        "Testicular Abnominalies",
        "Polyps"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 174,
      "start_date": "2016-07",
      "completion_date": "2022-08-31",
      "has_results": false,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-11-02T04:51:10.850Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02831556"
    },
    {
      "nct_id": "NCT01008319",
      "title": "Traditional Clomiphene Citrate Administration vs. Stair-step Approach",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovulatory Dysfunction",
        "Anovulation",
        "Ovulation Induction"
      ],
      "interventions": [
        {
          "name": "clomiphene citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2009-10",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2018-01-08",
      "last_synced_at": "2026-11-02T04:51:10.850Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01008319"
    },
    {
      "nct_id": "NCT02537444",
      "title": "Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Acalabrutinib",
          "type": "DRUG"
        },
        {
          "name": "acalabrutinib and pembrolizumab combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acerta Pharma BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 78,
      "start_date": "2015-11",
      "completion_date": "2018-10",
      "has_results": true,
      "last_update_posted_date": "2019-09-25",
      "last_synced_at": "2026-11-02T04:51:10.850Z",
      "location_count": 2,
      "location_summary": "Tucson, Arizona • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02537444"
    }
  ]
}